Genmab A/S Announces Progress With DuoBody(TM) Platform

COPENHAGEN, Denmark, Dec. 20, 2011 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced today that the company has entered a research collaboration with an as yet undisclosed, new large pharmaceutical partner to investigate a bispecific antibody-drug conjugate using Genmab's DuoBody technology in combination with a novel antibody-drug conjugate technology platform from the pharma company. If successful, the parties may decide to enter into a license agreement to further develop a new DuoBody-ADC product. The target in the collaboration is clinically validated and expressed on solid tumors.

Back to news